Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study ; volume:7 ; number:4 ; day:16 ; month:11 ; year:2020 ; pages:1021-1035 ; date:12.2020
Rheumatology and therapy ; 7, Heft 4 (16.11.2020), 1021-1035, 12.2020
- Creator
-
Smolen, Josef S.
Sebba, Anthony
Ruderman, Eric M.
Schulze-Koops, Hendrik
Sapin, Christophe
Gellett, Amanda M.
Sprabery, Aubrey Trevelin
Li, Lingnan
Torre, Inmaculada de la
Gallo, Gaia
Liu-Leage, Soyi
Pillai, Sreekumar
Reis, Paulo
Nash, Peter
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-020-00250-3
- URN
-
urn:nbn:de:101:1-2021010719263530389991
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Smolen, Josef S.
- Sebba, Anthony
- Ruderman, Eric M.
- Schulze-Koops, Hendrik
- Sapin, Christophe
- Gellett, Amanda M.
- Sprabery, Aubrey Trevelin
- Li, Lingnan
- Torre, Inmaculada de la
- Gallo, Gaia
- Liu-Leage, Soyi
- Pillai, Sreekumar
- Reis, Paulo
- Nash, Peter
- SpringerLink (Online service)
Other Objects (12)
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis